Effect of Pravastatin on Angiographic Restenosis After Coronary Balloon Angioplasty fn1fn1This study was supported by a grant from Bristol Myers Squibb Laboratories, Paris

• Published in: Journal of the American College of Cardiology Vol. 30; no. 4; pp. 863 - 869
• Main Authors: Bertrand, Michel E., McFadden, Eugène P., Fruchart, Jean-Charles, Van Belle, Eric, Commeau, Philippe, Grollier, Gilles, Bassand, Jean-Pierre, Machecourt, Jacques, Cassagnes, Jean, Mossard, Jean-Marie, Vacheron, André, Castaigne, Alain, Danchin, Nicolas, Lablanche, Jean-Marc
• Format: Journal Article
• Language: English
• Published: Elsevier Inc 01.10.1997
• Subjects: HDL; CAESAR; MLD; LDL; PREDICT; PTCA; CABG; CARE; Lp(a); LRT
• ISSN: 0735-1097; 1558-3597
• DOI: 10.1016/S0735-1097(97)00259-3

Objectives. This study sought to determine whether pravastatin affects clinical or angiographic restenosis after coronary balloon angioplasty. Background. Experimental data and preliminary clinical studies suggest that lipid-lowering drugs might have a beneficial effect on restenosis after coronary angioplasty. Methods. In a multicenter, randomized, double-blind trial, 695 patients were randomized to receive pravastatin (40 mg/day) or placebo for 6 months after successful balloon angioplasty. All patients received aspirin (100 mg/day). The primary angiographic end point was minimal lumen diameter (MLD) at follow-up, assessed by quantitative coronary angiography. A sample size of 313 patients per group was required to demonstrate a difference of 0.13 mm in MLD between groups (allowing for a two-tailed alpha error of 0.05 and a beta error of 0.20). To allow for incomplete angiographic follow-up (estimated lost to follow-up rate of 10%), 690 randomized patients were required. Secondary end points were angiographic restenosis rate (restenosis assessed as a categoric variable, >50% stenosis) and clinical events (death, myocardial infarction, target vessel revascularization). Results. At baseline, clinical, demographic, angiographic and lipid variables did not differ significantly between groups. In patients treated with pravastatin, there was a significant reduction in total and low density lipoprotein cholesterol and triglyceride levels and a significant increase in high density lipoprotein cholesterol levels. At follow-up the MLD (mean ± SD) was 1.47 ± 0.62 mm in the placebo group and 1.54 ± 0.66 mm in the pravastatin group (p = 0.21). Similarly, late loss and net gain did not differ significantly between groups. The restenosis rate (recurrence >50% stenosis) was 43.8% in the placebo group and 39.2% in the pravastatin group (p = 0.26). Clinical restenosis did not differ significantly between groups. Conclusions. Although pravastatin has documented efficacy in reducing clinical events and angiographic disease progression in patients with coronary atherosclerosis, this study shows that it has no effect on angiographic outcome at the target site 6 months after coronary angioplasty.